Hovione announces New Pharma Campus expansion in New Jersey

EAST WINDSOR, N.J., Nov. 22, 2021 /PRNewswire/ -- Hovione, the global leader in spray drying and particle engineering announced that it is expanding its New Jersey site in East Windsor, laying the foundations for a state-of-the-art Hovione Campus. This expansion in New Jersey will create up to 100 jobs over the next few years is part of a global expansion strategy representing an investment of $170million in increasing its capacity at its sites in the USA, Ireland and Portugal and was recently announced by Guy Villax, Chief Executive Officer, and Jean-Luc Herbeaux, Chief Operating Officer at Hovione.

In New Jersey, Hovione will add a 31,000 sqft building next to its current facility in East Windsor, New Jersey, laying the foundations for a state-of-the-art Hovione Campus. This investment will bring additional commercial spray drying capacity online by 2023. The expansion will allow the company to respond to the needs of customers who favor US-based manufacturing through their development cycles all the way to commercial. Additionally, it will solidify the Hovione's integrated offer: API - Particle Engineering - Drug Product in the region.

"Hovione has set the goal of becoming the leading company provider of innovative and integrated solutions for the global pharmaceutical industry by 2028. Given its dimension and above all, the extremely high regulatory requirements, the US market is fundamental for the company and this investment represents a key step in our expansion strategy" says Filipe Tomás, General Manager at Hovione in New Jersey. He adds that "Hovione was established more than 60 years ago in Portugal and the company's sustainable organic growth has allowed us to strive for excellence, rigor, innovation and quality. Present in the US since 2002, we have ensured that these values remain at the forefront of what we do at the New Jersey site".

About Hovione
Hovione is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization (CDMO) and is currently a fully integrated supplier offering services for drug substance, drug product intermediate and drug product. With four FDA inspected sites in the USA, China, Ireland and Portugal and development laboratories in Lisbon, Portugal and New Jersey, USA, the company provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs including highly potent compounds. For generic pharmaceutical customers the company offers niche API products. Hovione also provides proprietary product development and licensing opportunities for drug products. In the inhalation area, Hovione is the only independent company offering a complete range of services. 

Contact
Isabel Pina | Director External Communications
[email protected] | Tel.: +351 21 982 9362

Notes to Editor

Hovione was established in 1959 in Portugal and employs 2,000 globally in four countries (Portugal, USA, Ireland and China).

The Hovione New Jersey site commenced operations in 2002 providing process development and small volume API manufacturing and since then its technologies portfolio has evolved with the addition of highly potent compound handling and particle engineering capabilities. The site was first inspected by the FDA in 2007 and has been regularly inspected since.

Hovione cares about the environment and is deeply committed to sustainability being the first chemical/pharmaceutical company to be a certified B Corp. It uses 100% renewable energy onsite endeavouring to reduce its carbon footprint. The site was rewarded with VPP Star Award by the Occupational Safety and Health Administration (OSHA) in 2007 and has successfully maintained this status since. Hovione New Jersey is certified for the Customs-Trade Partnership Against Terrorism (C-TPAT) by the U.S. Customs and Border Protection (CBP).

SOURCE Hovione